Allogene Therapeutics, Inc. (ALLO)
Develops cancer-fighting immune cells genetically engineered from donor cells.
$1.64-0.07%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+51.4%
The outlook
Analysts overwhelmingly favor ALLO with a Strong Buy consensus, and the average price target sits roughly 450% above the current price. However, the stock is trading well below both its 50- and 200-day moving averages and sits near the low end of its 52-week range, reflecting recent weakness. The overall sentiment is mixed between bullish analyst views and bearish technical positioning.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 9 analysts
Price trendBelow its 50- & 200-day averages
52-week range19% of the way from its 52-week low to high
Price targetAvg target +450% vs current price
Analyst price target
~12-month · 9 analysts$9.00average target+450.5% vs now
Now $1.64
Low $4.00High $14.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$564.3M
52-wk high
$4.46
52-wk low
$0.98
50-day avg
$1.98
200-day avg
$1.85
Trailing P/E
—